<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific <z:chebi fb="0" ids="26995">thromboxane</z:chebi> <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, was assessed in patients previously treated with aspirin for the prevention of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This double-blind, parallel-group, 10-day study included 48 patients (age = 70.5 +/- 9.5 years) with cerebral ischemic event and/or <z:hpo ids='HP_0100546'>carotid stenosis</z:hpo> in 4 groups: terutroban 10 mg/day (n = 13), aspirin 300 mg/day (n = 12), terutroban 10 mg/day + aspirin 300 mg/day (n = 11) or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> 75 mg/day + aspirin 300 mg/day (n = 12) </plain></SENT>
<SENT sid="2" pm="."><plain>The measurements included parameters from an ex vivo model of <z:mp ids='MP_0005048'>thrombosis</z:mp>, platelet aggregation in platelet-rich plasma and plasma biomarkers of endothelial/platelet activation </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Between days 0 and 10, the mean cross-sectional surface of dense <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> significantly decreased with terutroban (58%, p = 0.001), terutroban + aspirin (63%, p = 0.005) and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> + aspirin (61%, p &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>On day 10, the value for terutroban was significantly lower than that for aspirin (p &lt; 0.01) and was comparable to the dual therapy terutroban + aspirin or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> + aspirin </plain></SENT>
<SENT sid="5" pm="."><plain>Similar results were found for total <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> surface and platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Platelet aggregation induced by the specific <z:chebi fb="0" ids="26995">thromboxane</z:chebi> <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> U46619 was almost completely inhibited on day 10 in both terutroban groups but not in the others </plain></SENT>
<SENT sid="7" pm="."><plain>As regards markers of endothelial/platelet activation or lesions, thrombomodulin significantly increased and plasma soluble P selectin significantly decreased by day 10 in both terutroban groups, whereas the <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor did not change significantly </plain></SENT>
<SENT sid="8" pm="."><plain>Terutroban was found to be safe and well TOLERATED </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Terutroban has demonstrated an antithrombotic activity that is superior to aspirin and similar to <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> + aspirin; it induces a significant in vivo reduction in endothelial/platelet activation </plain></SENT>
</text></document>